Material for separation of a biomolecule
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9561252-B2
Publication Date
2017-02-07
Expiration Date
Abstract
A Product is described and which contains at least one type of ligand bound to a separation material and which allows selective binding or cleavage of a biomolecule for example in human blood.
Core Innovation
The invention relates to a combined product for selective binding and cleavage of biomolecules in human blood or plasma. The combined product includes a column and a matrix filled into the column, where at least one blood group A saccharide specific to bind to anti-A antibodies and/or at least one blood group B saccharide specific to bind to anti-B antibodies are bound to the matrix, optionally via a spacer.
The matrix further comprises at least one hydrolytic enzyme with specificity to cleave a blood group A saccharide, a blood group B saccharide, or combinations thereof. The described matrix embodiments include agarose/Sepharose variants and optional magnetic matrices, and the spacer functional groups enable binding of the saccharides to the matrix.
In the described use contexts, the combined product is employed for extracorporeal treatment of human blood and/or blood plasma via column processing, to achieve removal or reduction of blood proteins and antibodies and generate universal plasma, including AB-plasma and blood group O conversion. The document also describes pairing the ligand-bound matrix with enzymes for cleavage, including IgG/IgM degrading enzymes and proteolytic enzymes for blood plasma treatment, and specifically hydrolytic enzyme embodiments such as IdeS and N-acetyl-α-D-galactosaminidase and α-D-galactosidase.
Claims Coverage
The independent claim covers a combined column product that integrates ligand-bound blood group A and/or B saccharides for selective antibody binding and hydrolytic enzyme(s) configured to cleave the corresponding blood group saccharides, within a human blood or plasma column format. One inventive feature is identified.
Combined product for selective binding and cleavage in human blood or plasma
A combined product for selective binding and cleavage of biomolecules in human blood or plasma comprising a column and a matrix filled into the column; at least one blood group A saccharide with specificity to bind to anti-A antibodies and/or at least one blood group B saccharide with specificity to bind to anti-B antibodies are bound to the matrix, optionally via a spacer; and the matrix further comprises at least one hydrolytic enzyme with specificity to cleave a blood group A saccharide, a blood group B saccharide, or combinations thereof.
Overall claim coverage centers on integrating antibody-binding blood group A/B saccharides on a column matrix, optionally through a spacer, with hydrolytic enzyme(s) specific for cleavage of those blood group saccharides, configured for processing human blood or plasma.
Stated Advantages
Reduction/removal of blood proteins and antibodies to generate universal plasma.
Conversion of blood group A and/or blood group B saccharides to blood group O saccharides.
Obtaining a blood product comprising blood group O red blood cells with decreased anti-A and/or anti-B antibody levels compared to before passing through the combined product.
Documented Applications
Extracorporeal treatment of human blood and/or blood plasma by passing through the combined product in a column format.
Treatment of donated blood of blood group A, B, or AB by passing it through the combined product to obtain a blood product comprising blood group O red blood cells with decreased anti-A and/or anti-B antibody levels.
Generation of universal plasma, including AB-plasma, by reduction/removal of blood proteins and antibodies during processing.
Interested in licensing this patent?